Merck & Co Inc (MRK.N) said on Monday that it has sought emergency use approval in the United States for its medicine to treat fairly benign COVID-19 patients, putting it on track to become the first oral antiviral therapy for the illness.
Because the tablet may be taken at home, approval from the US Food and Drug Administration might assist improve the clinical care of COVID-19.
The firms stated in a statement Monday that an application for molnupiravir to treat mild-to-moderate Covid-19 in people at risk of developing a severe disease that may necessitate hospitalization has been filed with the Food and Drug Administration. Submissions to regulatory authorities across the world are planned in the coming months, following an interim review of clinical trial data that revealed it reduced the likelihood of hospitalization for such patients by half.
11 October 2021